{"ticker": {"uuid": "cd16b473-0635-4360-a6e5-0e625a23bbcb", "symbol": "PRTA", "name": "Prothena Corporation plc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Trading the Move, Not the Narrative: (PRTA) Edition", "summary": "This article analyzes Prothena Corporation Plc (NASDAQ: PRTA), highlighting weak near-term sentiment but strong mid- and long-term outlooks, suggesting potential shifts. It details sophisticated AI-driven trading strategies including position, momentum breakout, and risk hedging,", "url": "https://news.stocktradersdaily.com/news_release/141/Trading_the_Move,_Not_the_Narrative:_PRTA_Edition_070926120201_1783612921.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-09T12:02:00", "published_display": "09 Jul 2026 12:02", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corp plc updates investors on pipeline progress as neurodegeneration focus deepens", "summary": "Prothena Corp plc, a clinical-stage biotechnology company, is updating investors on its pipeline progress in neurodegenerative diseases, particularly Alzheimer's and related disorders. The company specializes in developing therapies that target protein misfolding and is listed on", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/prothena-corp-plc-updates-investors-on-pipeline-progress-as/69715291", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T14:40:06", "published_display": "07 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Prothena Corporation plc \u2013 NASDAQ:PRTA", "summary": "This article provides a brief snapshot of the \"Price to sales forward\" for Prothena Corporation plc (NASDAQ: PRTA) as found on TradingView. It indicates that the market was closed at the time the data was accessed, and no trades were recorded for this specific metric. The content", "url": "https://www.tradingview.com/symbols/NASDAQ-PRTA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T12:39:18", "published_display": "04 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AL Amyloidosis Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Sorrento Therapeutics, Prothena Therapeutics, Spectrum Pharma, Takeda", "summary": "DelveInsight's \"AL Amyloidosis Pipeline Insight, 2026\" report details over 10 companies developing 10+ therapies for AL Amyloidosis, covering clinical trials, mechanisms of action, and FDA approvals. Key developments include orphan drug designation for Attralus, Inc.'s zamubafusp", "url": "https://www.barchart.com/story/news/3075869/al-amyloidosis-pipeline-2026-therapies-under-investigation-clinical-trials-milestones-and-fda-approvals-by-delveinsight-sorrento-therapeutics-prothena-therapeutics-spectrum-pharma-takeda", "source_name": "Barchart.com", "published_at": "2026-07-01T12:09:38", "published_display": "01 Jul 2026 12:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PRTA - Prothena Corp Plc Options", "summary": "This article provides a detailed financial overview of Prothena Corp Plc (PRTA), including its stock performance, key financial metrics, and insider/institutional ownership data. It highlights the company's market capitalization, income, sales, and various valuation ratios, along", "url": "https://finviz.com/stock?t=PRTA&ta=0&p=w&ty=oc&ov=list_strike&s=16", "source_name": "Finviz", "published_at": "2026-07-01T08:10:04", "published_display": "01 Jul 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Prothena Corporation plc \u2013 NASDAQ:PRTA", "summary": "This article provides financial data, specifically the price-to-earnings forward ratio, for Prothena Corporation plc (NASDAQ:PRTA). It is a brief data point from TradingView's financial overview for the biotechnology company. The content appears to be a stub or a data lookup resu", "url": "https://www.tradingview.com/symbols/NASDAQ-PRTA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T01:08:59", "published_display": "29 Jun 2026 01:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(PRTA) Volatility Zones as Tactical Triggers", "summary": "This article analyzes Prothena Corporation Plc (NASDAQ: PRTA) using AI models, highlighting strong sentiment across all horizons and identifying a mid-channel oscillation pattern. It presents three distinct trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014with spe", "url": "https://news.stocktradersdaily.com/news_release/150/PRTA_Volatility_Zones_as_Tactical_Triggers_062826105401_1782658441.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-28T11:08:59", "published_display": "28 Jun 2026 11:08", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Prothena Corp. Plc \u2013 MUN:0PT", "summary": "This article displays the \"Price to sales forward\" metric for Prothena Corp. Plc (MUN:0PT). It presents the period, value, change, and change percentage for this financial indicator. The content largely consists of a placeholder table for financial data and navigation elements.", "url": "https://www.tradingview.com/symbols/MUN-0PT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T22:39:38", "published_display": "27 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Prothena Corporation plc \u2013 NASDAQ:PRTA", "summary": "This page from TradingView provides financial information for Prothena Corporation plc (NASDAQ: PRTA). It specifically highlights the company's price to book forward metric, offering a snapshot of its financial valuation. The content focuses on market data and financial tools ava", "url": "https://www.tradingview.com/symbols/NASDAQ-PRTA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T16:39:38", "published_display": "27 Jun 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Prothena Corporation plc \u2013 NASDAQ:PRTA", "summary": "This article provides the enterprise value to revenue forward for Prothena Corporation plc (NASDAQ:PRTA). It lists the stock on the Nasdaq Stock Market and includes general information about its financial metrics. The original content appears to be a stub or a section of a larger", "url": "https://www.tradingview.com/symbols/NASDAQ-PRTA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T10:08:45", "published_display": "27 Jun 2026 10:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Prothena Corporation plc \u2013 NASDAQ:PRTA", "summary": "This article provides financial data for Prothena Corporation plc (NASDAQ: PRTA), specifically focusing on its enterprise value to EBIT forward. It presents this metric in a table format, showing the period, value, change, and percentage change. The content appears to be a financ", "url": "https://www.tradingview.com/symbols/NASDAQ-PRTA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T09:08:45", "published_display": "27 Jun 2026 09:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Prothena Corp. Plc \u2013 MUN:0PT", "summary": "This article provides financial data for Prothena Corp. Plc (MUN:0PT), specifically focusing on its \"Price to book forward\" metric. The content highlights the company's financial overview on the Munich Stock Exchange, indicating market status and data source information.", "url": "https://www.tradingview.com/symbols/MUN-0PT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T05:08:45", "published_display": "27 Jun 2026 05:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Prothena Corporation plc \u2013 NASDAQ:PRTA", "summary": "This article provides current financial data for Prothena Corporation plc (NASDAQ: PRTA), specifically focusing on its enterprise value to EBITDA forward metric. The information is presented through TradingView, a financial platform offering various market tools and data. The pag", "url": "https://www.tradingview.com/symbols/NASDAQ-PRTA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T00:40:00", "published_display": "27 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corp, Parkinson antibody program draws attention for the stock", "summary": "Prothena Corp (PRTA) is gaining investor attention due to its Parkinson's disease antibody, prasinezumab, developed in partnership with Roche. The company is focused on neurodegenerative diseases, and analysts are closely watching upcoming clinical milestones and the competitive ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/prothena-corp-parkinson-antibody-program-draws-attention-for-the-stock/69634525", "source_name": "Ad-hoc-news.de", "published_at": "2026-06-26T15:40:00", "published_display": "26 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corp. Plc Actuals & Estimates (NASDAQ:PRTA)", "summary": "This article provides an overview of Prothena Corporation plc (NASDAQ: PRTA) stock, including its current price, market capitalization, and analyst forecasts. It details financial performance metrics like earnings per share and revenue for past quarters, and offers information on", "url": "https://www.tradingview.com/symbols/NASDAQ-PRTA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:40:00", "published_display": "26 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corporation PLC (PRTA) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Prothena Corporation PLC (PRTA) has a strong financial score of 9.21, ranking 10th in its industry, indicating robust financial health and high operating efficiency. The company reported a significant year-over-year revenue increase of 1706.36% to $51.08 million and a net profit ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-prta/financial-health", "source_name": "TradingKey", "published_at": "2026-06-25T02:40:00", "published_display": "25 Jun 2026 02:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corporation PLC (PRTA) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Prothena Corporation PLC (PRTA), detailing its support and resistance levels, price momentum score, and various technical indicator and moving average signals. As of June 26, 2026, PRTA has a price momentum score of 6.29, trading betw", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-prta/technical", "source_name": "TradingKey", "published_at": "2026-06-24T15:40:27", "published_display": "24 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corporation Plc (NASDAQ:PRTA) About To Shift From Loss To Profit", "summary": "The article discusses Prothena Corporation Plc (NASDAQ:PRTA) and its anticipated shift from a loss to a profit. It examines the company's historical earnings, future growth prospects, and the factors contributing to its expected profitability. This transition is highlighted as a ", "url": "https://news.futunn.com/en/post/74962520/prothena-corporation-plc-nasdaq-prta-about-to-shift-from-loss", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-06-24T01:41:14", "published_display": "24 Jun 2026 01:41", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corp plc strategy in focus, shares watched against biotech peers", "summary": "Prothena Corp plc (PRTA) is a late-stage neuroscience biotech company listed on Nasdaq, specializing in antibody therapies for neurodegenerative diseases like Alzheimer's, Parkinson's, and amyloidosis. The company's strategy involves partnerships with major pharmaceutical firms s", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/prothena-corp-plc-strategy-in-focus-shares-watched-against-biotech-peers/69604598", "source_name": "AD HOC NEWS", "published_at": "2026-06-22T18:09:20", "published_display": "22 Jun 2026 18:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corporation PLC (PRTA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Prothena Corporation PLC (PRTA), detailing its earnings forecast score, average price target, and analyst ratings. It highlights that the company's current earnings forecast score is 6.67, ranking 327 out of 389 in its industry, with", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-prta/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T12:10:45", "published_display": "18 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corporation PLC (PRTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for Prothena Corporation PLC (PRTA). It indicates that relevant business segment and regional revenue data have not yet been disclosed by the company. The page displays basic stock information including market cap and curr", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-prta/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T06:18:13", "published_display": "18 Jun 2026 06:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corporation PLC (PRTA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Prothena Corporation PLC's (PRTA) dividend and stock split history, noting that no dividend data is available for the past five years and no stock split data is recorded. It highlights the company's current stock price, market capitalization, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-prta/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T06:18:13", "published_display": "18 Jun 2026 06:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corporation PLC (PRTA) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Prothena Corporation PLC (PRTA), listing major individual and institutional holders, their proportions, and changes in their holdings. It also categorizes shareholder types and provides data on institutional shareholding over vari", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-prta/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T06:18:13", "published_display": "18 Jun 2026 06:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corporation PLC (PRTA) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Prothena Corporation PLC (PRTA), noting its current valuation score of 6.53 within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -3.18, and states that relevant data for P/B, P/S, and P/CF ra", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-prta/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T23:40:11", "published_display": "17 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corporation PLC (PRTA) Institutional Confidence", "summary": "Prothena Corporation PLC (PRTA) has a strong institutional confidence score of 10.00, ranking first in the Biotechnology & Medical Research industry. The company's institutional shareholding proportion is 96.24%, an increase of 19.52% quarter-over-quarter. Fidelity Management & R", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-prta/sentiment", "source_name": "TradingKey", "published_at": "2026-06-16T22:40:47", "published_display": "16 Jun 2026 22:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ten percent owner of Prothena (NASDAQ: PRTA) acquires 125,000 shares in open-market buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNMHZsdXBrenNIZFE5eFh3WDVuV1F1Z1hTYU56Sl9oS3dSQjgtRDQ4R1ZacVlDN3dieUtNRVI1MVN6Yl9WenNSN2ZXa05ESkNheTAyVHJJTVhUMWVBUGRLTVNLQi1XTmh5SmhDcTFQSkpfdnJRYVloLXA3azF0S1dmU01jMnBEWDNJTWk2VXRIUVVDdHcySWUzS3R0aVFSbElReFhoTWZRT0NVTXRtVkY4X3h5OVdicEdIZjE3YnF3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena (NASDAQ: PRTA) counsel details ordinary share and option stakes", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQU01CSEFZdHhiQndhVnotSWZIMFVCYWUzVXFXYWRDSFN5YUppNmxueTAxeGJFQXc2M2REdUp0NUpqTTJpUWZxX213T2Nqd2JfYlBpM3pLSG5NTGtUSE1hbnRxRHBuTEdldkU5RFlfRkVqYk93b0k4emJ6TUkyejA0cnVjSHJ1MzBGUG84blFjVWdiay05LXZoLUxkdURCQW5Va1FENnozcGZqVVV3NlZfbFQtX1doNTFTTVVjZnlHbWdob1FYLThNNkEyOA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] PROTHENA CORP PUBLIC LTD CO SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPOUFPanAwUTlNVWRwUVpldnVXUzBvcFljR0ZLbXdLMmU5TlZuVEFmV1FHeWdaUlhPTld3dEJVZEwxODktMUt5X0R1TXlBMkRVcHZ6QWt1T0RLZ05MY1BqU3lGLVd1b19BOVVoZGxURFM5djRhdFZSa2dKVmVhN0hVMlozN3k0TWlBb01Wel96SS1HWmlLOFlVMm50Z0Q1dmNDa3NOYXBLMA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(PRTA) Price Dynamics and Execution-Aware Positioning", "summary": "This article provides an analysis of Prothena Corporation Plc (NASDAQ: PRTA) using AI models to determine price dynamics and optimal positioning. It highlights weak near-term sentiment but strong long-term prospects, offering distinct institutional trading strategies for differen", "url": "https://news.stocktradersdaily.com/news_release/8/PRTA_Price_Dynamics_and_Execution-Aware_Positioning_060626081202_1780747922.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-06T08:10:07", "published_display": "06 Jun 2026 08:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corp Public Ltd Insider Bought Shares Worth $465,295, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/prothena-corp-public-ltd-insider-175358974.html", "source_name": "MT Newswires", "published_at": "2026-06-05T17:53:58+00:00", "published_display": "05 Jun 2026 17:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corp Public Ltd Co (PRTA) holder buys 50,000 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPVU5KNFhHbUJVZTlMa0tkZEYyWWV0eV9zcFMwQmM5d0FBS0tKeWdmUGQ2a1FjaWFQclpNbjItSXlMb3ZDaHYyajhMaDEwQk9TbFV1UUFvRnlNZ29HVEpVdzZCY0tRcmJub1dkNjU1eGdzYjhhOGFseHNmSjM2SEtwTDZaYWRXVURPdjJ3WlliT0lja3VXMGd0MDZPaE1fWm56dWxwd1YzdVRjV2VaOUpEWHYxcGltaXdTOTJMS3ln?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PRTA - Prothena Corp Plc Stock Price and Quote", "summary": "This article provides comprehensive financial data, stock performance metrics, and news updates for Prothena Corp Plc (PRTA). It includes details on market capitalization, income, sales, key ratios, analyst ratings, and insider transactions, offering a detailed overview of the co", "url": "https://finviz.com/stock?t=PRTA", "source_name": "Finviz", "published_at": "2026-06-05T06:39:19", "published_display": "05 Jun 2026 06:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corp Public Ltd Insider Bought Shares Worth $471,300, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/prothena-corp-public-ltd-insider-165047223.html", "source_name": "MT Newswires", "published_at": "2026-06-03T16:50:47+00:00", "published_display": "03 Jun 2026 16:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Insider Bought Shares Worth $981,300, According to a Recent SEC Filing", "summary": "An insider at Prothena Corporation PLC recently purchased shares totaling $981,300, according to a recent SEC filing. This transaction occurred on May 26, 2026. The company is a late-stage clinical biotechnology firm focused on protein dysregulation and neurological diseases.", "url": "https://www.marketscreener.com/news/prothena-insider-bought-shares-worth-981-300-according-to-a-recent-sec-filing-ce7f5ad2db8ef327", "source_name": "marketscreener.com", "published_at": "2026-05-26T15:01:00", "published_display": "26 May 2026 15:01", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rubric Capital and David Rosen disclose 9.29% stake in Prothena (PRTA)", "summary": "Rubric Capital Management LP and David Rosen have collectively disclosed a 9.29% stake in Prothena Corporation plc (PRTA), holding 5,000,000 Ordinary Shares with shared voting and dispositive power. This information comes from a Schedule 13G/A SEC filing, which also indicates tha", "url": "https://www.stocktitan.net/sec-filings/PRTA/schedule-13g-a-prothena-corp-public-ltd-co-amended-passive-investment-f29e8fe8d59a.html", "source_name": "Stock Titan", "published_at": "2026-05-15T20:09:52", "published_display": "15 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena (NASDAQ: PRTA) investors approve board, KPMG and executive pay", "summary": "Prothena Corporation plc shareholders re-elected two directors, Shane M. Cooke and Dennis J. Selkoe, to the Board until 2029. They also ratified KPMG LLP as the independent registered public accounting firm for fiscal year 2026 and approved the compensation of the company's named", "url": "https://www.stocktitan.net/sec-filings/PRTA/8-k-prothena-corp-public-ltd-co-reports-material-event-1b7041244b08.html", "source_name": "Stock Titan", "published_at": "2026-05-15T20:09:52", "published_display": "15 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Beat: Prothena Corporation plc Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQV3o4alB4SVBCZUNZVjFOVG9hTER0amFtbWZHZURTSmlRbFNVZVpscTNyRkVaOEFrbW9JU3BpU2tOMWRHalNiQzJBYmgwUzJyZXZGOFVGZ254cGtrMTdRQTUtYmR4NTVrMmk5X3czZFdGc2hDYW5VZzh3TmVMZzBrMDh0VnJGa3ptTVRLd3VGS2s5Y3JOMURhOU9JUlFjRmFPd0QzTC13?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Prothena Posts Q1 Earnings as Revenues Surge on Milestone Payment", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPQlZXOEM1ZEVLeEFQRXQtRFJvNDA2aXBMM0RkT0RjQ2w4azdObjFCbG1hNXc4UDlRSkVjWGNmVEp2ZDk1ZjJBMlVyal9WLWZpUzdjWTlJWWxFVFpIMjdzU0RBQnJvZm5UZlZHTmxJZFZCa0JpU1JtU0FXdjlKZGpxUTBCMmQ3ampPMWZwbjZncDRKcFN4UWpYVnliNllXdnNXcmhrLUhlbw?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/prothena-q1-earnings-snapshot-204308915.html", "source_name": "Associated Press", "published_at": "2026-05-07T20:43:08+00:00", "published_display": "07 May 2026 20:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Reports First Quarter 2026 Financial Results and Business Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxQYUxfejJuVVpJX29kQU91clVfcjNyWHM0dV96WjhpOTg1OTB4b1ZnRmpjUGdPMkd0VWFTVS1BbmlLWjJFS0t4X293VGVkNVBPYlpfNjhaSUFDRDFpMXpBR1gtS3o5SjVKZGZFZEREZkZ0ZmpsMWkyNnBwSnN4TkVSeVUwLVpOVjMyc3pxMkg1SVJZc0ExX3JUcjNoV3ZhV2Vhb21HbGNwT2FaZmpFQWp3ZVNUaWoxYWtFR0NpbFlBUVg0VHlRRGNzNUR4MmtRcUk?oc=5", "source_name": "Business Wire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Wall Street Analysts Think Prothena (PRTA) Could Surge 120.19%: Read This Before Placing a Bet", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOLXE3cUZyOGhnUlpqOHllR0RKdGw1UkpUaUNhNEgyeDRhRjA0dU9LV1gxUXNveC1FWU1va3VuUzNLQVFucnpDblIxWmp0V1dUeGZlc1FVaFBuZUNWbTF6TWVpVnQybkUwdlNsa3dJSzIzN2pGd0FQUmg2Q0ZsZGw2Qm4xUDhOdUZYMDZXV2ZjbkVsNU9xZVMzdUVNWFA1cmhRWFE?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Prothena stock rating on Parkinson\u2019s data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPbE84SVhLMGF3UFlRajF1VjZncV9oZHJQbjY1b2tWcnZFeWNsNENVODZxQVRaVFJsVUI5VndEcFozdHhuRjIzSkhab1I5bW1Xa1hRcGhrbVdmRVNBQndkMmd3R1p4T3J0OWhnY08xZVlNOWUxNzhFYzF4b0FTRFhfLUtUendiLUFaVk1CZ2NOU0VKcndrOThybzJaak1iaHBBdHNBN2IyRXZ0OHUyenhGelJjM3RJU2o5R1VZdnRBdzZhRjQ?oc=5", "source_name": "Investing.com", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novo Nordisk coramitug trial milestone brings Prothena $50M", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNQXZrR3I2OUNFOXF1eTFBbUY1Nkc1cG1lZlBjeTk1RnhfSl96UWlMM2dSSmdZZ0xoY1V6T1R4YkluaUNzbE1mTVFXZzNxaXBHMnVZU2RNRFJSOWJzbTJ6eEIwcVV1YTVHdWh5bHRWY2hqTUdEaGdyTzhrS0JCd25DNkgxdXZRbG9LZDVBMEhYTjFUSUh2SVNqQWVUSUk2bFFYdTdHdDRZQ1FOOWFONTBwYXg1SGxDY3NuSVE?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena: A Hold With 2 Late-Stage Programs Underway But With Caution (NASDAQ:PRTA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNbGRkNFl2SHdXZHhsaHRnelQ0OXBIRHpBYU9nQnBMQU9rdDEyVHZLR1hsaUdTSFQ0MThMZmdCVGRzV1d1Z3dlMjVsRXhVSkkyR0UzcVQyS0RTdE1rTnlZdm5KVTlnU2xvRGJhMHh2bElWZTB2cEdDS3B4anJBT18wblRfbVNQdkRwbDdsdUd2ZnY0VVNvY3pDN19vaUg0Nkk5eVdNR1dzZU9JbW9abFE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Stock Tumbles 36.8% Year Over Year: What Lies Ahead?", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE1aMzZia2lQeW9hZ2FWMTVpMEpKMTVtbFJtVWVfM1NhTUJIVjREVThONDlTNS14ajN2bldVaTdITlpmXzRCeUxzR0phSlc4UGdMaDVNT3Nac3RPazBIaERYTUFPM3UzelhJRkQ2MHo0SWlZYUstR0ZOczFrWGgwdw?oc=5", "source_name": "Market source", "published_at": "2026-02-16T08:00:00+00:00", "published_display": "16 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena (PRTA) Stock Forecast and Price Target 2026 $PRTA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTFBpUk9kOWs3VUxWZnV5cWV0bWdKUm1LRFptOHRQTFZuZHRXWHpQSjBIZXRDV29TbFVSY3pOWGp5dENtX3Y2emZGRkNXbEV4ZlZ0TThtYXNORUUtZTl5Tmc0YjBfSmNTdw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T14:07:58+00:00", "published_display": "11 May 2024 14:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Billy Dunn\u2019s Prothena Board Position Reignites Ethical Debate", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPOW5kVmJjUXc2UGVPb09kYjhoWWRiXzR5VE5oNUgtT1JKemE3ZEEtM3BpMkpxM2JVNjFmbms5LU9kTUVuY2JpX0hOV1Y4Mk9zSUtvOEtEWEJSRjRnd05UaG1YczNESTRrek1KVzZTWU5LUzdWQ3NQbDhUUEJycG1sc0w1anVxYkRDNktvNy1LUQ?oc=5", "source_name": "BioSpace", "published_at": "2023-05-23T07:00:00+00:00", "published_display": "23 May 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PRTA Stock Price and Chart \u2014 NASDAQ:PRTA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5CVTFIOWZTVUo5RXJDWjNVMUJyS25IcldmSFd5NzRzMW54ajIzMkRhTTU1eGtVcWN3aGQ1cnhFWW1BTGU1R0dRblpiS1JpQk5ES0JWd1FDRzluTER0?oc=5", "source_name": "TradingView", "published_at": "2021-03-03T08:00:00+00:00", "published_display": "03 Mar 2021 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Trading the Move, Not the Narrative: (PRTA) Edition", "summary": "This article analyzes Prothena Corporation Plc (NASDAQ: PRTA), highlighting weak near-term sentiment but strong mid- and long-term outlooks, suggesting potential shifts. It details sophisticated AI-driven trading strategies including position, momentum breakout, and risk hedging,", "url": "https://news.stocktradersdaily.com/news_release/141/Trading_the_Move,_Not_the_Narrative:_PRTA_Edition_070926120201_1783612921.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-09T12:02:00", "published_display": "09 Jul 2026 12:02", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corp plc updates investors on pipeline progress as neurodegeneration focus deepens", "summary": "Prothena Corp plc, a clinical-stage biotechnology company, is updating investors on its pipeline progress in neurodegenerative diseases, particularly Alzheimer's and related disorders. The company specializes in developing therapies that target protein misfolding and is listed on", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/prothena-corp-plc-updates-investors-on-pipeline-progress-as/69715291", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T14:40:06", "published_display": "07 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Prothena Corporation plc \u2013 NASDAQ:PRTA", "summary": "This article provides a brief snapshot of the \"Price to sales forward\" for Prothena Corporation plc (NASDAQ: PRTA) as found on TradingView. It indicates that the market was closed at the time the data was accessed, and no trades were recorded for this specific metric. The content", "url": "https://www.tradingview.com/symbols/NASDAQ-PRTA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T12:39:18", "published_display": "04 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AL Amyloidosis Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Sorrento Therapeutics, Prothena Therapeutics, Spectrum Pharma, Takeda", "summary": "DelveInsight's \"AL Amyloidosis Pipeline Insight, 2026\" report details over 10 companies developing 10+ therapies for AL Amyloidosis, covering clinical trials, mechanisms of action, and FDA approvals. Key developments include orphan drug designation for Attralus, Inc.'s zamubafusp", "url": "https://www.barchart.com/story/news/3075869/al-amyloidosis-pipeline-2026-therapies-under-investigation-clinical-trials-milestones-and-fda-approvals-by-delveinsight-sorrento-therapeutics-prothena-therapeutics-spectrum-pharma-takeda", "source_name": "Barchart.com", "published_at": "2026-07-01T12:09:38", "published_display": "01 Jul 2026 12:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PRTA - Prothena Corp Plc Options", "summary": "This article provides a detailed financial overview of Prothena Corp Plc (PRTA), including its stock performance, key financial metrics, and insider/institutional ownership data. It highlights the company's market capitalization, income, sales, and various valuation ratios, along", "url": "https://finviz.com/stock?t=PRTA&ta=0&p=w&ty=oc&ov=list_strike&s=16", "source_name": "Finviz", "published_at": "2026-07-01T08:10:04", "published_display": "01 Jul 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Prothena Corporation plc \u2013 NASDAQ:PRTA", "summary": "This article provides financial data, specifically the price-to-earnings forward ratio, for Prothena Corporation plc (NASDAQ:PRTA). It is a brief data point from TradingView's financial overview for the biotechnology company. The content appears to be a stub or a data lookup resu", "url": "https://www.tradingview.com/symbols/NASDAQ-PRTA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T01:08:59", "published_display": "29 Jun 2026 01:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(PRTA) Volatility Zones as Tactical Triggers", "summary": "This article analyzes Prothena Corporation Plc (NASDAQ: PRTA) using AI models, highlighting strong sentiment across all horizons and identifying a mid-channel oscillation pattern. It presents three distinct trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014with spe", "url": "https://news.stocktradersdaily.com/news_release/150/PRTA_Volatility_Zones_as_Tactical_Triggers_062826105401_1782658441.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-28T11:08:59", "published_display": "28 Jun 2026 11:08", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Prothena Corp. Plc \u2013 MUN:0PT", "summary": "This article displays the \"Price to sales forward\" metric for Prothena Corp. Plc (MUN:0PT). It presents the period, value, change, and change percentage for this financial indicator. The content largely consists of a placeholder table for financial data and navigation elements.", "url": "https://www.tradingview.com/symbols/MUN-0PT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T22:39:38", "published_display": "27 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Prothena Corporation plc \u2013 NASDAQ:PRTA", "summary": "This page from TradingView provides financial information for Prothena Corporation plc (NASDAQ: PRTA). It specifically highlights the company's price to book forward metric, offering a snapshot of its financial valuation. The content focuses on market data and financial tools ava", "url": "https://www.tradingview.com/symbols/NASDAQ-PRTA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T16:39:38", "published_display": "27 Jun 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Prothena Corporation plc \u2013 NASDAQ:PRTA", "summary": "This article provides the enterprise value to revenue forward for Prothena Corporation plc (NASDAQ:PRTA). It lists the stock on the Nasdaq Stock Market and includes general information about its financial metrics. The original content appears to be a stub or a section of a larger", "url": "https://www.tradingview.com/symbols/NASDAQ-PRTA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T10:08:45", "published_display": "27 Jun 2026 10:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Prothena Corporation plc \u2013 NASDAQ:PRTA", "summary": "This article provides financial data for Prothena Corporation plc (NASDAQ: PRTA), specifically focusing on its enterprise value to EBIT forward. It presents this metric in a table format, showing the period, value, change, and percentage change. The content appears to be a financ", "url": "https://www.tradingview.com/symbols/NASDAQ-PRTA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T09:08:45", "published_display": "27 Jun 2026 09:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Prothena Corp. Plc \u2013 MUN:0PT", "summary": "This article provides financial data for Prothena Corp. Plc (MUN:0PT), specifically focusing on its \"Price to book forward\" metric. The content highlights the company's financial overview on the Munich Stock Exchange, indicating market status and data source information.", "url": "https://www.tradingview.com/symbols/MUN-0PT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T05:08:45", "published_display": "27 Jun 2026 05:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Prothena Corporation plc \u2013 NASDAQ:PRTA", "summary": "This article provides current financial data for Prothena Corporation plc (NASDAQ: PRTA), specifically focusing on its enterprise value to EBITDA forward metric. The information is presented through TradingView, a financial platform offering various market tools and data. The pag", "url": "https://www.tradingview.com/symbols/NASDAQ-PRTA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T00:40:00", "published_display": "27 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corp, Parkinson antibody program draws attention for the stock", "summary": "Prothena Corp (PRTA) is gaining investor attention due to its Parkinson's disease antibody, prasinezumab, developed in partnership with Roche. The company is focused on neurodegenerative diseases, and analysts are closely watching upcoming clinical milestones and the competitive ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/prothena-corp-parkinson-antibody-program-draws-attention-for-the-stock/69634525", "source_name": "Ad-hoc-news.de", "published_at": "2026-06-26T15:40:00", "published_display": "26 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corp. Plc Actuals & Estimates (NASDAQ:PRTA)", "summary": "This article provides an overview of Prothena Corporation plc (NASDAQ: PRTA) stock, including its current price, market capitalization, and analyst forecasts. It details financial performance metrics like earnings per share and revenue for past quarters, and offers information on", "url": "https://www.tradingview.com/symbols/NASDAQ-PRTA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:40:00", "published_display": "26 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corporation PLC (PRTA) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Prothena Corporation PLC (PRTA) has a strong financial score of 9.21, ranking 10th in its industry, indicating robust financial health and high operating efficiency. The company reported a significant year-over-year revenue increase of 1706.36% to $51.08 million and a net profit ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-prta/financial-health", "source_name": "TradingKey", "published_at": "2026-06-25T02:40:00", "published_display": "25 Jun 2026 02:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corporation PLC (PRTA) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Prothena Corporation PLC (PRTA), detailing its support and resistance levels, price momentum score, and various technical indicator and moving average signals. As of June 26, 2026, PRTA has a price momentum score of 6.29, trading betw", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-prta/technical", "source_name": "TradingKey", "published_at": "2026-06-24T15:40:27", "published_display": "24 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corporation Plc (NASDAQ:PRTA) About To Shift From Loss To Profit", "summary": "The article discusses Prothena Corporation Plc (NASDAQ:PRTA) and its anticipated shift from a loss to a profit. It examines the company's historical earnings, future growth prospects, and the factors contributing to its expected profitability. This transition is highlighted as a ", "url": "https://news.futunn.com/en/post/74962520/prothena-corporation-plc-nasdaq-prta-about-to-shift-from-loss", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-06-24T01:41:14", "published_display": "24 Jun 2026 01:41", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corp plc strategy in focus, shares watched against biotech peers", "summary": "Prothena Corp plc (PRTA) is a late-stage neuroscience biotech company listed on Nasdaq, specializing in antibody therapies for neurodegenerative diseases like Alzheimer's, Parkinson's, and amyloidosis. The company's strategy involves partnerships with major pharmaceutical firms s", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/prothena-corp-plc-strategy-in-focus-shares-watched-against-biotech-peers/69604598", "source_name": "AD HOC NEWS", "published_at": "2026-06-22T18:09:20", "published_display": "22 Jun 2026 18:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corporation PLC (PRTA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Prothena Corporation PLC (PRTA), detailing its earnings forecast score, average price target, and analyst ratings. It highlights that the company's current earnings forecast score is 6.67, ranking 327 out of 389 in its industry, with", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-prta/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T12:10:45", "published_display": "18 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corporation PLC (PRTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for Prothena Corporation PLC (PRTA). It indicates that relevant business segment and regional revenue data have not yet been disclosed by the company. The page displays basic stock information including market cap and curr", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-prta/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T06:18:13", "published_display": "18 Jun 2026 06:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corporation PLC (PRTA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Prothena Corporation PLC's (PRTA) dividend and stock split history, noting that no dividend data is available for the past five years and no stock split data is recorded. It highlights the company's current stock price, market capitalization, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-prta/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T06:18:13", "published_display": "18 Jun 2026 06:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corporation PLC (PRTA) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Prothena Corporation PLC (PRTA), listing major individual and institutional holders, their proportions, and changes in their holdings. It also categorizes shareholder types and provides data on institutional shareholding over vari", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-prta/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T06:18:13", "published_display": "18 Jun 2026 06:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corporation PLC (PRTA) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Prothena Corporation PLC (PRTA), noting its current valuation score of 6.53 within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -3.18, and states that relevant data for P/B, P/S, and P/CF ra", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-prta/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T23:40:11", "published_display": "17 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corporation PLC (PRTA) Institutional Confidence", "summary": "Prothena Corporation PLC (PRTA) has a strong institutional confidence score of 10.00, ranking first in the Biotechnology & Medical Research industry. The company's institutional shareholding proportion is 96.24%, an increase of 19.52% quarter-over-quarter. Fidelity Management & R", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-prta/sentiment", "source_name": "TradingKey", "published_at": "2026-06-16T22:40:47", "published_display": "16 Jun 2026 22:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ten percent owner of Prothena (NASDAQ: PRTA) acquires 125,000 shares in open-market buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNMHZsdXBrenNIZFE5eFh3WDVuV1F1Z1hTYU56Sl9oS3dSQjgtRDQ4R1ZacVlDN3dieUtNRVI1MVN6Yl9WenNSN2ZXa05ESkNheTAyVHJJTVhUMWVBUGRLTVNLQi1XTmh5SmhDcTFQSkpfdnJRYVloLXA3azF0S1dmU01jMnBEWDNJTWk2VXRIUVVDdHcySWUzS3R0aVFSbElReFhoTWZRT0NVTXRtVkY4X3h5OVdicEdIZjE3YnF3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena (NASDAQ: PRTA) counsel details ordinary share and option stakes", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQU01CSEFZdHhiQndhVnotSWZIMFVCYWUzVXFXYWRDSFN5YUppNmxueTAxeGJFQXc2M2REdUp0NUpqTTJpUWZxX213T2Nqd2JfYlBpM3pLSG5NTGtUSE1hbnRxRHBuTEdldkU5RFlfRkVqYk93b0k4emJ6TUkyejA0cnVjSHJ1MzBGUG84blFjVWdiay05LXZoLUxkdURCQW5Va1FENnozcGZqVVV3NlZfbFQtX1doNTFTTVVjZnlHbWdob1FYLThNNkEyOA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] PROTHENA CORP PUBLIC LTD CO SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPOUFPanAwUTlNVWRwUVpldnVXUzBvcFljR0ZLbXdLMmU5TlZuVEFmV1FHeWdaUlhPTld3dEJVZEwxODktMUt5X0R1TXlBMkRVcHZ6QWt1T0RLZ05MY1BqU3lGLVd1b19BOVVoZGxURFM5djRhdFZSa2dKVmVhN0hVMlozN3k0TWlBb01Wel96SS1HWmlLOFlVMm50Z0Q1dmNDa3NOYXBLMA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(PRTA) Price Dynamics and Execution-Aware Positioning", "summary": "This article provides an analysis of Prothena Corporation Plc (NASDAQ: PRTA) using AI models to determine price dynamics and optimal positioning. It highlights weak near-term sentiment but strong long-term prospects, offering distinct institutional trading strategies for differen", "url": "https://news.stocktradersdaily.com/news_release/8/PRTA_Price_Dynamics_and_Execution-Aware_Positioning_060626081202_1780747922.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-06T08:10:07", "published_display": "06 Jun 2026 08:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corp Public Ltd Insider Bought Shares Worth $465,295, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/prothena-corp-public-ltd-insider-175358974.html", "source_name": "MT Newswires", "published_at": "2026-06-05T17:53:58+00:00", "published_display": "05 Jun 2026 17:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corp Public Ltd Co (PRTA) holder buys 50,000 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPVU5KNFhHbUJVZTlMa0tkZEYyWWV0eV9zcFMwQmM5d0FBS0tKeWdmUGQ2a1FjaWFQclpNbjItSXlMb3ZDaHYyajhMaDEwQk9TbFV1UUFvRnlNZ29HVEpVdzZCY0tRcmJub1dkNjU1eGdzYjhhOGFseHNmSjM2SEtwTDZaYWRXVURPdjJ3WlliT0lja3VXMGd0MDZPaE1fWm56dWxwd1YzdVRjV2VaOUpEWHYxcGltaXdTOTJMS3ln?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PRTA - Prothena Corp Plc Stock Price and Quote", "summary": "This article provides comprehensive financial data, stock performance metrics, and news updates for Prothena Corp Plc (PRTA). It includes details on market capitalization, income, sales, key ratios, analyst ratings, and insider transactions, offering a detailed overview of the co", "url": "https://finviz.com/stock?t=PRTA", "source_name": "Finviz", "published_at": "2026-06-05T06:39:19", "published_display": "05 Jun 2026 06:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Corp Public Ltd Insider Bought Shares Worth $471,300, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/prothena-corp-public-ltd-insider-165047223.html", "source_name": "MT Newswires", "published_at": "2026-06-03T16:50:47+00:00", "published_display": "03 Jun 2026 16:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Insider Bought Shares Worth $981,300, According to a Recent SEC Filing", "summary": "An insider at Prothena Corporation PLC recently purchased shares totaling $981,300, according to a recent SEC filing. This transaction occurred on May 26, 2026. The company is a late-stage clinical biotechnology firm focused on protein dysregulation and neurological diseases.", "url": "https://www.marketscreener.com/news/prothena-insider-bought-shares-worth-981-300-according-to-a-recent-sec-filing-ce7f5ad2db8ef327", "source_name": "marketscreener.com", "published_at": "2026-05-26T15:01:00", "published_display": "26 May 2026 15:01", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rubric Capital and David Rosen disclose 9.29% stake in Prothena (PRTA)", "summary": "Rubric Capital Management LP and David Rosen have collectively disclosed a 9.29% stake in Prothena Corporation plc (PRTA), holding 5,000,000 Ordinary Shares with shared voting and dispositive power. This information comes from a Schedule 13G/A SEC filing, which also indicates tha", "url": "https://www.stocktitan.net/sec-filings/PRTA/schedule-13g-a-prothena-corp-public-ltd-co-amended-passive-investment-f29e8fe8d59a.html", "source_name": "Stock Titan", "published_at": "2026-05-15T20:09:52", "published_display": "15 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena (NASDAQ: PRTA) investors approve board, KPMG and executive pay", "summary": "Prothena Corporation plc shareholders re-elected two directors, Shane M. Cooke and Dennis J. Selkoe, to the Board until 2029. They also ratified KPMG LLP as the independent registered public accounting firm for fiscal year 2026 and approved the compensation of the company's named", "url": "https://www.stocktitan.net/sec-filings/PRTA/8-k-prothena-corp-public-ltd-co-reports-material-event-1b7041244b08.html", "source_name": "Stock Titan", "published_at": "2026-05-15T20:09:52", "published_display": "15 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Beat: Prothena Corporation plc Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQV3o4alB4SVBCZUNZVjFOVG9hTER0amFtbWZHZURTSmlRbFNVZVpscTNyRkVaOEFrbW9JU3BpU2tOMWRHalNiQzJBYmgwUzJyZXZGOFVGZ254cGtrMTdRQTUtYmR4NTVrMmk5X3czZFdGc2hDYW5VZzh3TmVMZzBrMDh0VnJGa3ptTVRLd3VGS2s5Y3JOMURhOU9JUlFjRmFPd0QzTC13?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Posts Q1 Earnings as Revenues Surge on Milestone Payment", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPQlZXOEM1ZEVLeEFQRXQtRFJvNDA2aXBMM0RkT0RjQ2w4azdObjFCbG1hNXc4UDlRSkVjWGNmVEp2ZDk1ZjJBMlVyal9WLWZpUzdjWTlJWWxFVFpIMjdzU0RBQnJvZm5UZlZHTmxJZFZCa0JpU1JtU0FXdjlKZGpxUTBCMmQ3ampPMWZwbjZncDRKcFN4UWpYVnliNllXdnNXcmhrLUhlbw?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/prothena-q1-earnings-snapshot-204308915.html", "source_name": "Associated Press", "published_at": "2026-05-07T20:43:08+00:00", "published_display": "07 May 2026 20:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Reports First Quarter 2026 Financial Results and Business Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxQYUxfejJuVVpJX29kQU91clVfcjNyWHM0dV96WjhpOTg1OTB4b1ZnRmpjUGdPMkd0VWFTVS1BbmlLWjJFS0t4X293VGVkNVBPYlpfNjhaSUFDRDFpMXpBR1gtS3o5SjVKZGZFZEREZkZ0ZmpsMWkyNnBwSnN4TkVSeVUwLVpOVjMyc3pxMkg1SVJZc0ExX3JUcjNoV3ZhV2Vhb21HbGNwT2FaZmpFQWp3ZVNUaWoxYWtFR0NpbFlBUVg0VHlRRGNzNUR4MmtRcUk?oc=5", "source_name": "Business Wire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Think Prothena (PRTA) Could Surge 120.19%: Read This Before Placing a Bet", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOLXE3cUZyOGhnUlpqOHllR0RKdGw1UkpUaUNhNEgyeDRhRjA0dU9LV1gxUXNveC1FWU1va3VuUzNLQVFucnpDblIxWmp0V1dUeGZlc1FVaFBuZUNWbTF6TWVpVnQybkUwdlNsa3dJSzIzN2pGd0FQUmg2Q0ZsZGw2Qm4xUDhOdUZYMDZXV2ZjbkVsNU9xZVMzdUVNWFA1cmhRWFE?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Prothena stock rating on Parkinson\u2019s data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPbE84SVhLMGF3UFlRajF1VjZncV9oZHJQbjY1b2tWcnZFeWNsNENVODZxQVRaVFJsVUI5VndEcFozdHhuRjIzSkhab1I5bW1Xa1hRcGhrbVdmRVNBQndkMmd3R1p4T3J0OWhnY08xZVlNOWUxNzhFYzF4b0FTRFhfLUtUendiLUFaVk1CZ2NOU0VKcndrOThybzJaak1iaHBBdHNBN2IyRXZ0OHUyenhGelJjM3RJU2o5R1VZdnRBdzZhRjQ?oc=5", "source_name": "Investing.com", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novo Nordisk coramitug trial milestone brings Prothena $50M", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNQXZrR3I2OUNFOXF1eTFBbUY1Nkc1cG1lZlBjeTk1RnhfSl96UWlMM2dSSmdZZ0xoY1V6T1R4YkluaUNzbE1mTVFXZzNxaXBHMnVZU2RNRFJSOWJzbTJ6eEIwcVV1YTVHdWh5bHRWY2hqTUdEaGdyTzhrS0JCd25DNkgxdXZRbG9LZDVBMEhYTjFUSUh2SVNqQWVUSUk2bFFYdTdHdDRZQ1FOOWFONTBwYXg1SGxDY3NuSVE?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena: A Hold With 2 Late-Stage Programs Underway But With Caution (NASDAQ:PRTA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNbGRkNFl2SHdXZHhsaHRnelQ0OXBIRHpBYU9nQnBMQU9rdDEyVHZLR1hsaUdTSFQ0MThMZmdCVGRzV1d1Z3dlMjVsRXhVSkkyR0UzcVQyS0RTdE1rTnlZdm5KVTlnU2xvRGJhMHh2bElWZTB2cEdDS3B4anJBT18wblRfbVNQdkRwbDdsdUd2ZnY0VVNvY3pDN19vaUg0Nkk5eVdNR1dzZU9JbW9abFE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena Stock Tumbles 36.8% Year Over Year: What Lies Ahead?", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE1aMzZia2lQeW9hZ2FWMTVpMEpKMTVtbFJtVWVfM1NhTUJIVjREVThONDlTNS14ajN2bldVaTdITlpmXzRCeUxzR0phSlc4UGdMaDVNT3Nac3RPazBIaERYTUFPM3UzelhJRkQ2MHo0SWlZYUstR0ZOczFrWGgwdw?oc=5", "source_name": "Market source", "published_at": "2026-02-16T08:00:00+00:00", "published_display": "16 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prothena (PRTA) Stock Forecast and Price Target 2026 $PRTA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTFBpUk9kOWs3VUxWZnV5cWV0bWdKUm1LRFptOHRQTFZuZHRXWHpQSjBIZXRDV29TbFVSY3pOWGp5dENtX3Y2emZGRkNXbEV4ZlZ0TThtYXNORUUtZTl5Tmc0YjBfSmNTdw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T14:07:58+00:00", "published_display": "11 May 2024 14:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Billy Dunn\u2019s Prothena Board Position Reignites Ethical Debate", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPOW5kVmJjUXc2UGVPb09kYjhoWWRiXzR5VE5oNUgtT1JKemE3ZEEtM3BpMkpxM2JVNjFmbms5LU9kTUVuY2JpX0hOV1Y4Mk9zSUtvOEtEWEJSRjRnd05UaG1YczNESTRrek1KVzZTWU5LUzdWQ3NQbDhUUEJycG1sc0w1anVxYkRDNktvNy1LUQ?oc=5", "source_name": "BioSpace", "published_at": "2023-05-23T07:00:00+00:00", "published_display": "23 May 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PRTA Stock Price and Chart \u2014 NASDAQ:PRTA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5CVTFIOWZTVUo5RXJDWjNVMUJyS25IcldmSFd5NzRzMW54ajIzMkRhTTU1eGtVcWN3aGQ1cnhFWW1BTGU1R0dRblpiS1JpQk5ES0JWd1FDRzluTER0?oc=5", "source_name": "TradingView", "published_at": "2021-03-03T08:00:00+00:00", "published_display": "03 Mar 2021 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 101, "total_relevant": 56, "sentiment_summary": {"positive": 15, "negative": 5, "neutral": 36, "score": 54, "total": 56, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 16.3, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 9.7, "count": 19}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 15, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 9.24, "latest_week": "2026-07-10", "one_week_move": -4.6, "four_week_move": 12.0, "twelve_week_move": -15.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.309869, "market_dynamics_buy_signal": false, "relative_strength": -15.178891, "fair_value_gap": -52.7, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 46.0169, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.6% over one week, +12.0% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 11}, {"label": "Market source", "count": 9}, {"label": "TradingKey", "count": 8}, {"label": "Stock Titan", "count": 7}, {"label": "Stock Traders Daily", "count": 3}, {"label": "AD HOC NEWS", "count": 2}, {"label": "Finviz", "count": 2}, {"label": "MT Newswires", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 48}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 19}, {"label": "Analyst action", "count": 3}, {"label": "Deals and strategy", "count": 2}, {"label": "Regulatory and legal", "count": 1}, {"label": "Capital return", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "48", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-4.6% over one week, +12.0% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Trading the Move, Not the Narrative: (PRTA) Edition"}], "updated_at": "2026-07-16T00:45:55.649775+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}